TickerGuard
Buy Day today: Neutral (48) Mixed market breadth · no major macro event
ODTX

Odyssey Therapeutics, Inc.

Healthcare · Biotechnology

21.50$ +4.7% vs. previous close Closing price · As of: Sep 28, 2026

Ownership

Ownership Structure

Who owns Odyssey Therapeutics, Inc. (ODTX)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 49.2% of the shares are freely tradable; institutional investors hold 51.2%.

Institutional ownership ?Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings. 51.2%
Insiders ?Share of the stock held by the executives, founders and major shareholders of the company itself. 6.1%
Float ?Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders. 49.2%
Short % of float ?Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices. 5.3%
Shares Outstanding ?Total number of shares issued. Price times share count gives market cap. 48Mio.

Largest Shareholders

Institutions

Institutions ODTX
Name Stake (%) Shares Change (%) Date
SR ONE CAPITAL MANAGEMENT, LP 7.90 3,794,883 +0.0 06/30/2026
Lightspeed Management Co LLC 7.51 3,608,443 +0.0 06/30/2026
Sanofi 4.14 1,991,918 +0.0 06/30/2026
Sands Capital Ventures, LLC 1.82 875,000 +0.0 06/30/2026
Hillhouse Capital Advisors, Ltd. 1.73 831,656 +0.0 06/30/2026
General Catalyst Group Management, LLC 1.69 810,272 +0.0 06/30/2026
Affinity Asset Advisors, LLC 1.59 766,346 +0.0 06/30/2026
Adage Capital Partners Gp LLC 1.51 725,000 +0.0 06/30/2026
Foresite Capital Management V, LLC 1.48 713,105 +0.0 06/30/2026

Funds

Funds ODTX
Name Stake (%) Shares Change (%) Date
Fidelity Growth Company Fund 2.15 1,033,434 +28.2 07/31/2026

Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.

Data as of: September 28, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?